Cara Therapeutic Stock Performance
| CARA Stock | USD 0.71 0.02 2.74% |
On a scale of 0 to 100, Cara Therapeutic holds a performance score of 6. The firm shows a Beta (market volatility) of 5.39, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cara Therapeutic will likely underperform. Please check Cara Therapeutic's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Cara Therapeutic's price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cara Therapeutic are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Cara Therapeutic sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:2 | Last Split Date 2014-01-16 |
1 | Will Cara Therapeutics Inc Lag the Rest of the Stocks in the Healthcare Sector - InvestorsObserver | 01/29/2024 |
2 | Acquisition by Scott Terrillion of 13500 shares of Cara Therapeutic subject to Rule 16b-3 | 02/05/2024 |
3 | Disposition of 3293 shares by Joana Goncalves of Cara Therapeutic at 0.89 subject to Rule 16b-3 | 02/29/2024 |
4 | Cara Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 03/05/2024 |
5 | Analysts Have Made A Financial Statement On Cara Therapeutics, Inc.s Yearly Report | 03/07/2024 |
6 | Where Will Cara Therapeutics Inc Stock Go Next After It Has Fallen 9.89 percent in a Week - InvestorsObserver | 03/25/2024 |
7 | Disposition of 2753 shares by Scott Terrillion of Cara Therapeutic at 0.83 subject to Rule 16b-3 | 04/05/2024 |
8 | Disposition of 30000 shares by Makara Richard of Cara Therapeutic at 18.93 subject to Rule 16b-3 | 04/15/2024 |
| Begin Period Cash Flow | 64.1 M |
Cara |
Cara Therapeutic Relative Risk vs. Return Landscape
If you would invest 56.00 in Cara Therapeutic on January 25, 2024 and sell it today you would earn a total of 15.00 from holding Cara Therapeutic or generate 26.79% return on investment over 90 days. Cara Therapeutic is currently generating 0.6218% in daily expected returns and assumes 7.1547% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Cara, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cara Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cara Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cara Therapeutic, and traders can use it to determine the average amount a Cara Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0869
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CARA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.15 actual daily | 63 63% of assets are less volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cara Therapeutic is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cara Therapeutic by adding it to a well-diversified portfolio.
Cara Therapeutic Fundamentals Growth
Cara Stock prices reflect investors' perceptions of the future prospects and financial health of Cara Therapeutic, and Cara Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cara Stock performance.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (10.85) % | ||||
| Current Valuation | (18.94 M) | ||||
| Shares Outstanding | 54.67 M | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 1.99 X | ||||
| Revenue | 20.97 M | ||||
| Gross Profit | (56.14 M) | ||||
| EBITDA | (121.24 M) | ||||
| Net Income | (118.51 M) | ||||
| Cash And Equivalents | 157.51 M | ||||
| Cash Per Share | 2.93 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.32 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (92.08 M) | ||||
| Earnings Per Share | (2.19) X | ||||
| Market Capitalization | 38.66 M | ||||
| Total Asset | 125.84 M | ||||
| Retained Earnings | (684.75 M) | ||||
| Working Capital | 90.57 M | ||||
| Current Asset | 108.93 M | ||||
| Current Liabilities | 5.27 M | ||||
About Cara Therapeutic Performance
To evaluate Cara Therapeutic Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cara Therapeutic generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cara Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cara Therapeutic market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cara's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 160.06 | 140.62 | |
| Return On Tangible Assets | (0.94) | (0.89) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (0.94) | (0.89) | |
| Return On Equity | (2.08) | (1.97) |
Things to note about Cara Therapeutic performance evaluation
Checking the ongoing alerts about Cara Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cara Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cara Therapeutic is way too risky over 90 days horizon | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 30000 shares by Makara Richard of Cara Therapeutic at 18.93 subject to Rule 16b-3 |
- Analyzing Cara Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cara Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Cara Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cara Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cara Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cara Therapeutic's stock. These opinions can provide insight into Cara Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.